CHICAGO More is not better when it comes to inhibition of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC), the Alliance study shows.
Indeed, treating patients with both enzalutamide (Xtandi, Astellas) and abiraterone…
Read More
More Is Not Better in Metastatic CR Prostate Cancer – Medscape
